Healio Highlights Research From Dr. Truong-An (Andrew) Ho Presented at ERS Congress on the Reduction of NIV Utilization in Patients With COPD and Type II Inflammation Treated With Biologics

Healio highlighted research presented by Truong-An (Andrew) Ho, MD, a Pulmonary and Critical Care Fellow at the Temple Lung Center, at the European Respiratory Society (ERS) Congress in Amsterdam, which showed that in a real-world cohort of patients with chronic obstructive pulmonary disease (COPD) and type II inflammation, treatment with biologics was associated with a significant reduction in non-invasive ventilation (NIV) utilization and a trend toward decreased ICU admissions. The findings suggest that biologics may reduce the burden of the most severe exacerbations.